Liang Caihua, Polkowska-Kramek Aleksandra, Lade Caroline, Bayer Lea J, Bruyndonckx Robin, Huebbe Bennet, Ewnetu Worku Biyadgie, Peerawaranun Pimnara, Casas Maribel, Tran Thao Mai Phuong, Brestrich Gordon, von Eiff Christof, Gessner Bradford D, Begier Elizabeth, Rohde Gernot
Pfizer Inc, New York, New York, USA.
P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
Influenza Other Respir Viruses. 2025 May;19(5):e70097. doi: 10.1111/irv.70097.
RSV incidence in adults is frequently underestimated due to non-specific symptomatology, limited standard-of-care testing, and lower test sensitivity compared to infants. We conducted a retrospective observational study to estimate RSV-attributable incidence of specific types of cardiorespiratory hospitalizations among adults in Germany between 2015 and 2019.
Information on hospitalizations and the number of people at risk of hospitalization (denominator) was gathered from a Statutory Health Insurance database. A quasi-Poisson regression model accounting for periodic and aperiodic time trends and virus activity was fitted to estimate the RSV-attributable incidence rate (IR) of four specific cardiovascular hospitalizations (arrhythmia, ischemic heart diseases, chronic heart failure exacerbations, and cerebrovascular diseases) and four specific respiratory hospitalizations (influenza/pneumonia, bronchitis/bronchiolitis, chronic lower respiratory tract diseases, and upper respiratory tract diseases).
The estimated RSV-attributable IRs of hospitalizations generally increased with age. Among estimated cardiovascular hospitalizations in adults aged ≥ 60 years, arrhythmia and ischemic heart diseases accounted for the highest incidence of RSV-attributable events, followed by chronic heart failure exacerbation, with annual IR ranges of 157-260, 133-214, and 105-169 per 100,000 person-years, respectively. The most frequent RSV-attributable respiratory hospitalizations in adults aged ≥ 60 years were estimated for chronic lower respiratory tract diseases and bronchitis/bronchiolitis, with annual IR ranges of 103-168 and 77-122 per 100,000 person-years, respectively.
RSV causes a considerable burden of respiratory and cardiovascular hospitalizations in adults in Germany, similar to other respiratory viruses (e.g., influenza and SARS-CoV-2). This highlights the need to implement effective prevention strategies, especially for older adults.
由于症状不具特异性、标准护理检测有限以及与婴儿相比检测灵敏度较低，成人呼吸道合胞病毒（RSV）发病率常常被低估。我们开展了一项回顾性观察研究，以估算2015年至2019年间德国成人中特定类型心肺住院治疗的RSV归因发病率。
从法定健康保险数据库收集住院治疗信息以及住院风险人群数量（分母）。拟合一个考虑周期性和非周期性时间趋势以及病毒活性的准泊松回归模型，以估算四种特定心血管住院治疗（心律失常、缺血性心脏病、慢性心力衰竭加重和脑血管疾病）和四种特定呼吸道住院治疗（流感/肺炎、支气管炎/细支气管炎、慢性下呼吸道疾病和上呼吸道疾病）的RSV归因发病率（IR）。
住院治疗的估算RSV归因发病率一般随年龄增长而增加。在≥60岁成人的估算心血管住院治疗中，心律失常和缺血性心脏病的RSV归因事件发病率最高，其次是慢性心力衰竭加重，每年每10万人年的IR范围分别为157 - 260、133 - 214和105 - 169。在≥60岁成人中，最常见的RSV归因呼吸道住院治疗是慢性下呼吸道疾病和支气管炎/细支气管炎，每年每10万人年的IR范围分别为103 - 168和77 - 122。
在德国，RSV给成人带来了相当大的呼吸和心血管住院负担，与其他呼吸道病毒（如流感和SARS-CoV-2）类似。这凸显了实施有效预防策略的必要性，尤其是针对老年人。
